Literature DB >> 27218625

A Stronger Treatment System for Opioid Use Disorders.

Brendan Saloner1, Joshua Sharfstein2.   

Abstract

Mesh：

Year:  2016        PMID： 27218625     DOI： 10.1001/jama.2016.3674

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample.

Authors:  Noa Krawczyk; Kenneth A Feder; Michael I Fingerhood; Brendan Saloner
Journal:  Drug Alcohol Depend       Date:  2017-07-11       Impact factor: 4.492

2.  Overlapping buprenorphine, opioid, and benzodiazepine prescriptions among veterans dually enrolled in Department of Veterans Affairs and Medicare Part D.

Authors:  Walid F Gellad; Xinhua Zhao; Carolyn T Thorpe; Joshua M Thorpe; Florentina E Sileanu; John P Cashy; Maria Mor; Jennifer A Hale; Thomas Radomski; Leslie R M Hausmann; Michael J Fine; Chester B Good
Journal:  Subst Abus       Date:  2016-12-07       Impact factor: 3.716

3.  Overcoming medication stigma in peer recovery: A new paradigm.

Authors:  Noa Krawczyk; Tianna Negron; Maia Nieto; Deborah Agus; Michael I Fingerhood
Journal:  Subst Abus       Date:  2018-04-04       Impact factor: 3.716

4.  The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample.

Authors:  Noa Krawczyk; Kenneth A Feder; Brendan Saloner; Rosa M Crum; Marc Kealhofer; Ramin Mojtabai
Journal:  Drug Alcohol Depend       Date:  2017-04-19       Impact factor: 4.492

5.  Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment.

Authors:  Rebecca L Haffajee; Amy S B Bohnert; Pooja A Lagisetty
Journal:  Am J Prev Med       Date:  2018-06       Impact factor: 5.043
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.